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Abstract: Nelarabine is a nucleoside analog indicated for the treatment of adult and pediatric patients with T-cell acute lymphoblastic 
leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that is refractory or has relapsed after treatment with at least two che-
motherapy regimens. After being first synthesized in the late 1970s and receiving FDA approval in 2005, the appropriate use of nelara-
bine for refractory hematologic malignancies is still being elucidated. Nelarabine is the prodrug of 9-b-D-arabinofuranosylguanine 
(ara-G) which when phosphorylated intracellularly to ara-G triphosphate (ara-GTP), preferentially accumulates in cancerous T-cells. 
Dose-dependent toxicities, including neurotoxicity and myelosuppression, have been documented and may, in turn, limit the ability to 
appropriately treat the diagnosed malignancy. This article will summarize the pharmacologic properties of nelarabine and will address 
the current place in therapy nelarabine holds based upon the results of the available clinical trials to date.
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Introduction
According to the 2010 statistics from the American 
Cancer Society, there are 5,330 expected cases with 
1,420  expected  deaths  from  acute  lymphoblastic 
leukemia (ALL).1 Diagnosis peaks at ages 2–5 and 
approximately two-thirds of ALL cases are within this 
age population.2 ALL continues to be the most com-
mon malignancy in children less than 15 years old.1 
Complete remissions within this population is upward 
of 95% with 5-year disease-free survival (DFS) rates 
greater that 80%. And while the response and sur-
vival rates in the pediatric population are promising, 
the treatment of ALL in the adult population is much 
more difficult and shows much lower DFS rates, even 
with more aggressive chemotherapeutic regimens.2
A  subset  of ALL  includes  T-cell  lymphoblastic 
leukemia (T-ALL), which has shown to have a poorer 
prognosis due to a lesser response to initial chemo-
therapy and a high relapse rate.2 Treatment of T-ALL 
in the adult population has been the subject of recent 
study,  especially  in  the  patient  that  shows  either 
refractoriness or extensive disease. The current rec-
ommended regimens in the treatment of adult T-ALL 
include cyclophosphamide, doxorubicin, vincristine, 
and prednisone (CHOP) or a slight alteration on this 
regimen with the addition of etoposide (EPOCH) that 
includes some dose variation from CHOP.3 Some pro-
tocols suggest the use of a similar regimen of cyclo-
phosphamide, vicristine, doxorubicin, and prednisone 
(termed hyper-CVAD in this case) alternating with 
high-dose methotrexate and cytarabine. This regimen 
may be preferred in patients with CNS involvement 
or to prevent relapse within the CNS.3 Even with suc-
cessful remission subsequent to the above regimens, 
adult T-ALL patients show short times to relapse or 
recurrence and must often consider a hematopoietic 
stem cell transplant, which has significant side effects 
and can itself lessen the patient’s life span.2,3
A related malignancy to ALL is lymphoblastic lym-
phoma (LBL) which is considered an aggressive form 
of  non-Hodgkin’s  lymphoma. The  majority  of  LBL 
is of T-cell origin (T-LBL) and is treated similarly to 
T-ALL in regard to systemic chemotherapy. The risk of 
relapse and recurrence following appropriate therapy 
is high, with prognosis worsening in these patients.4 
With the problems associated with recurrent T-ALL 
and T-LBL, it is imperative that additional options for 
prolongation of response and survival be elucidated.
Nelarabine is a potential option to be included in the 
treatment of recurrent and/or relapsed T-ALL/T-LBL. 
Nelarabine is an antimetabolite based on a guanine 
nucleoside base residue. It is the prodrug of 9-b-D-
arabinofuranosyl guanine (ara-G) and was approved 
by the United States Food and Drug Administration in 
October of 2005. The approved indications for nelar-
abine are T-ALL and T-LBL in pediatric and adults 
patients that have refractory or progressive disease 
following  two  or  more  previous  chemotherapeutic 
regimens.5 The role of nelarabine in treating refrac-
tory hematologic malignancies is still being reviewed 
and studied. We will look to address what is known 
regarding nelarabine’s pharmacologic properties and 
the results from the clinical trials to date to further 
explain where nelarabine might be utilized for a dis-
ease state with limited options after previous treat-
ment failure.
Mechanism of Action  
and pharmacology
Nelarabine is a prodrug that after demethoxylation 
via adenosine deaminase, is converted to the com-
pound ara-G.6 In turn, ara-G is triphosphorylated by 
multiple kinases intracellularly to the active nucle-
otide, ara-GTP, which actively competes in leukemic 
blast cells for incorporation into cellular DNA.7,8 The 
resultant incorporation into leukemic cell DNA inhib-
its further DNA synthesis, although the specific loca-
tion of insertion has not been fully elucidated. This 
process prompts chain termination and programmed 
cell death leading to the clinical response (Fig. 1).6–8
The  preferential  accumulation  of  ara-GTP  in 
malignant T-cells helps to explain nelarabine’s clini-
cal activity in T-ALL and T-LBL. Although B-cells 
will accumulate ara-GTP, it is to a much lesser extent 
than with T-cells. This is explained partially by the 
reduced half-life of ara-GTP in B-cells when com-
pared  to  that  of  T-cells.10–12  The  cellular  toxicity 
induced by nelarabine provides for its efficacy as well 
as explains some of the adverse drug reactions associ-
ated with its use.
pharmacokinetics
Conversion of nelarabine to ara-G
The pharmacokinetics of nelarabine have been eval-
uated  in  refractory  hematologic  malignancies  in 
both pediatric and adult patients.13,14 As nelarabine, Nelarabine in refractory T-cell malignancies
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a   pro-drug, is typically administered as an intrave-
nous infusion, the maximum concentration (Cmax) is 
observed at the end of the infusion. The Cmax and 
area under the curve (AUC) of nelarabine are linearly 
related to the nelarabine dose over the range of 5 to 
75 mg/kg.13 Conversion of nelarabine to ara-G, cata-
lyzed by adenosine deaminase, is required to produce 
effective concentrations of ara-G which is converted 
intracellularly to the active nucleotide ara-GTP. As 
one mole of ara-G is converted from one mole of 
nelarabine, the elimination rate of nelarabine repre-
sents the formation rate of ara-G (Fig. 1).13 The half-
life (t½) of nelarabine is less than 20 minutes in most 
patients15 and is related to the efficient conversion to 
ara-G. Nelarabine is typically administered as a one 
or two-hour infusion. After one hour, approximately 
94% of nelarabine is converted to ara-G and after two 
hours, more than 99% of nelarabine is converted to 
ara-G.16 Table 1 summarizes the pharmacokinetics of 
nelarabine.
The  combination  of  nelarabine  and  fludarabine 
was examined to explore the potential of the clinical 
utility of the combination. The intent was to examine 
if fludarabine would modulate ara-G concentrations.16 
Nelarabine at the dose level of 1.2 g/m2 was given as 
an intravenous infusion on days one, three and five. 
On day one of treatment, nelarabine was administered 
alone. On days three and five, fludarabine (30 mg/m2) 
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Figure 1. Nelarabine is converted systemically to ara-G via adenosine deaminase. ara-G is transported into the leukemic blast by two different   transporters. 
One is a nitrobenzylthioinosoine sensitive (NBMPR+) transporter and the other is a nitrobenzylthioinosine insensitive (NBMPR-) transporter. The rate limit-
ing step in the formation of ara-GTP is the initial phosphorylation of ara-G to ara-GMP via both deoxyguanosine (dGuo) kinase and deoxycytidine (dCytd) 
kinase. Upon subsequent phosphorylation, ara-GTP competes with deoxyguanosine triphosphate (dGTP) for incorporation into DNA. Upon incorporation 
of ara-GTP into DNA, apoptosis occurs as formation is terminated.6–9Roecker et al
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was administered and nelarabine was given four hours 
later. Fludarabine had no influence on the pharma-
cokinetics of the parent compound (nelarabine) as the 
pharmacokinetics  of  nelarabine  when  administered 
alone or after fludarabine were similar.16 Fludarabine 
is not an inhibitor of or substrate for adenosine deam-
inase, thus, it was expected that the pharmacokinetics 
of nelarabine would not be altered by prior adminis-
tration of fludarabine.
Pharmacokinetics of ara-G
With efficient conversion of nelarabine to ara-G, the 
Cmax of ara-G also occurs at the end of the infu-
sion of nelarabine and is proportional to the admin-
istered dose of nelarabine. The AUC of ara-G is also 
related in a linear fashion to the dose of nelarabine.13 
As stated earlier, one mole of nelarabine would pro-
duce one mole of ara-G upon the demethoxylation 
of  nelarabine  by  adenosine  deaminase.  Therefore, 
a  linear  relationship  between  the  dose  of  nelara-
bine and the concentration of ara-G is expected. The 
plasma concentrations of ara-G decline with time in 
a mono-exponential fashion in both adult and pedi-
atric patients.13 The t½ of ara-G in pediatric patients 
(2.1 hrs) was shorter than in adult patients (3 hrs) as 
pediatric patients exhibit a higher clearance of ara-G 
relative  to  adult  patients  (Table  1).13 A  regression 
analysis of ara-G renal clearance and creatinine clear-
ance resulted in an r2 value of 0.25, indicating that the 
clearance of ara-G was weakly associated with crea-
tinine clearance.13 The clearance of nelarabine was 
lower (7%) in patients with creatinine clearances of 
50 to 80 mL/min.15 Although the pharmacokinetics of 
ara-G have not been studied in patients with severe 
renal dysfunction, it has been recommended that close 
monitoring for toxicity be performed in patients with 
creatinine clearances less than 50 mL/min.15 Mecha-
nistically, ara-G is metabolized to guanine by purine 
nucleoside  phosphorylase  (PNP).  Guanine  is  then 
converted via deamination to xanthine, which is then 
oxidized to form uric acid. With respect to the vol-
ume of distribution, no statistically significant differ-
ences were noted in the comparing pediatric to adult 
patients.13 Finally, the pharmacokinetics of ara-G are 
similar when comparing patients with various hema-
tologic malignancies.13
As  stated  previously,  the  pharmacokinetics  of 
ara-G  were  evaluated  in  the  face  of  combination 
therapy with nelarabine and fludarabine. The phar-
macokinetics of ara-G were determined on the first 
day of treatment (nelarabine alone), and on at least 
one subsequent day when nelarabine followed flu-
darabine  administration  by  four  hours.  The  t½  of 
ara-G when nelarabine was administered alone or in 
combination  with  fludarabine  was  similar.16 When 
comparing the Cmax and AUC of ara-G on day one 
(nelarabine  alone)  to  day  three  values  (nelarabine 
following  fludarabine),  the  Cmax  and  AUC  were 
slightly, but not statistically significantly higher with 
the   combination.16 Thus, fludarabine administration 
four hours prior to nelarabine dosing has no effect on 
the pharmacokinetics of ara-G.16
Pharmacokinetics of ara-GTP
Intracellular leukemic ara-GTP concentrations were 
evaluated  in  19  patients  with  various  hematologic 
Table 1. Pharmacokinetic parameter values (mean ± SD) for nelarabine, ara-G, ara-GTP.12–14
pediatric Adult
nelarabine
vd (L) 8.511 ± 11.518 4.197 ± 5.802 NSa
CL (L/kg/hr) 9.259 ± 12.794 5.875 ± 8.434 NSa
t½ (minutes) 14.1b 16.5b NSa
ara-G
vd (L) 1.023 ± 0.345 0.923 ± 0.231 NSa
CL (L/kg/hr) 0.312 ± 0.112 0.213 ± 0.072 P , 0.0001
t½ (hrs) 2.1b 3.0b P , 0.01
ara-GTp
Mean ara-GTP (μM) 435 ± 519 
746 ± 872c
t½ (hrs) .24bd
notes: aNo statistical difference; bHarmonic mean value; cNelarabine following fludarabine (combination); dPatient with T-cell disease.Nelarabine in refractory T-cell malignancies
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malignancies. The median Cmax value of ara-GTP 
was 23 μM/L, 42 μM/L, 85 μM/L, and 93 μM/L, with 
nelarabine doses 20 mg/kg, 30 mg/kg (1.2 g/m2 in adult 
patients), 40 mg/kg (1.2 g/m2 in pediatric patients), and 
60 mg/kg, respectively.12 The intracellular concentra-
tion of ara-GTP was greater in T-  lymphoblastic dis-
ease patients (n = 7; median 140 μM/L) as compared 
to other diagnoses (n = 9; 50 μM/L).14 It was noted 
that  the  leukemic  intracellular  concentrations  were 
higher than concentrations measured in normal mono-
nuclear cells (median 30 μM/L; n = 3).   Additionally, 
ara-GTP accumulated to a greater extent in leukemic 
T-cells and was retained for a longer time in leukemic 
T-cells from patients as compared to other types of 
leukemia cells.12
The  combination  of  fludarabine  and  nelarabine 
was intended to increase ara-GTP concentrations in 
leukemia cells that otherwise would not accumulate 
therapeutic  concentrations  of  this  active  triphos-
phate (malignant non-T-cells). A previous response to 
nelarabine in a patient with B-cell chronic lympho-
cytic leukemia (CLL) supported the examination of 
the combination of fludarabine and nelarabine.14 As 
stated earlier, nelarabine was administered intrave-
nously (1.2 g/m2) on days one, three, and five of a five 
day  regimen.  Fludarabine  (30  mg/m2)  was  admin-
istered  intravenously  on  days  three  and  five  over 
30 minutes four hours prior to nelarabine administra-
tion.16 It was proposed that fludarabine would inhibit 
ribonucleotide reductase and result in increased ara-
GTP  concentration.17  Accumulation  of  fludarabine 
triphosphate  (F-ara-ATP)  results  in  a  decrease  in 
deoxynucleotides,  including  deoxycytidine  triphos-
phate  (dCTP)  and  deoxyguanosine  triphosphate 
(dGTP).17 The decrease in deoxynucleotides results 
in  decreased  feed-back  inhibition  deoxynucleotide 
kinases18,19 resulting in an increase in the phosphory-
lation of ara-G to ara-GMP. The rate-limiting step in 
the formation of ara-GTP is the conversion of ara-G 
to ara-GMP. Therefore, combining fludarabine and 
nelarabine was proposed as a way to increase cellular 
concentrations of ara-GTP thus improving efficacy 
in  the  treatment  of  certain  non-T-cell  hematologic 
malignancies. Investigators noted a direct relationship 
between cellular F-ara-ATP (via fludarabine admin-
istration) and ara-GTP indicating modulation of the 
active nucleotide triphosphate. The half-life of ara-
GTP in this study was similar to earlier findings with 
the value in most patients being greater than 24 hours 
(median 35 hours).16
Clinical Efficacy
Treatment of refractory hematologic malignancies with 
nelarabine has been evaluated in a number of clinical 
trials. In the initial trial in both pediatric and adult leu-
kemia and lymphoma patients, a 5 day treatment course 
involving daily infusions was evaluated for efficacy.14 
A  dose  escalation  approach  was  utilized  to  address 
both treatment response as well as tolerability. Toxicity 
occurred at an unacceptable rate at doses of 75 mg/kg 
and above and the observed maximal tolerated dose of 
nelarabine in the adult population was 40 mg/kg and in 
the pediatric population was 60 mg/kg.14
The trial involved patients of multiple cell lin-
eages with 39 of 93 patients enrolled in the study 
showing either T-ALL or T-LBL. In this population, 
a complete response (CR) was achieved in 9 of the 39 
patients with the majority of those responses occur-
ring in the pediatric population (7 CRs in 26 pedi-
atric patients and 2 CRs in 13 adult patients).14 In 
addition to the CRs observed here, a partial response 
(PR)  was  achieved  in  another  12  of  39  patients 
resulting  in  a  total  of  53.8%  (21/39)  of  patients 
showing either a CR or PR. 15 of the 21 patients that 
had a response to nelarabine therapy were heavily 
treatment  experienced  showing  at  least  two  prior 
relapses and many had failed prior hematopoietic 
stem cell transplant.14 Total response was not lim-
ited solely to the T-cell malignancies, but only 1 CR 
and 7 PRs occurred outside the T-ALL and T-LBL 
patient groups. Regardless the specific diagnosis in 
this study, patient response occurred independent of 
the specific nelarabine dose.14
The  CALGB  19801  study  specifically  studied 
patients with T-cell malignancies. The study enrolled 
26 patients with T-ALL and 13 patients with T-LBL 
with all participants having either a relapse after a 
CR with prior therapy or showing refractoriness to 
at  least  one  induction  chemotherapy  regimen.20,21 
This  study  was  predominantly  in  the  adult  popu-
lation with the age range of 16 to 66 years in the 
trial.  Dosing  in  the  CALGB  19801  study  utilized 
1.5 g/m2 per dose for a total of three doses given on 
alternate days. Patients that achieved a CR following 
one course were given the option of continuing for 
two additional courses.20,21 Thirty-nine patients were Roecker et al
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evaluable with 16 showing either a CR or PR after 
nelarabine therapy. Thirty-one percent (8/26) of the 
T-ALL patients and 31% (4/13) of the T-LBL patients 
achieved a CR with a median DFS of 20 weeks sub-
sequent to treatment.20,21
A  National  Cancer  Institute-sponsored  phase  II 
study  of  nelarabine  in  non-Hodgkin’s  lymphoma 
was completed and evaluated by Goy, et al.22 The 
trial evaluated 23 patients with 13 of those diagnosed 
with T-LBL and all patients failing at least one pre-
vious chemotherapy regimen. The same dosing regi-
men from the CALGB 19801 trial was utilized here, 
although six cycles of nelarabine were administered 
with each cycle repeated every 28 days. Only 17 of 
23 patients were evaluable and two and six patients 
achieved a CR or PR, respectively. The individual 
responses  were  not  linked  directly  to  diagnosis  in 
this trial.22
Berg, et al evaluated nelarabine response in pedi-
atric patients with T-ALL and T-LBL.23 Toxicities in 
this trial limited the initial 153 patients in the trial to 
122 patients receiving the defined trial dosage level. 
Of those 122 patients, 106 patients were evaluable. 
This trial classified the study participants into four 
groups;  1)  Patients  refractory  to  initial  induction 
therapy or showing greater than 25% blasts in first 
relapse, 2) Patients showing greater than 25% blasts 
in a relapse subsequent to primary relapse, 3) Patients 
with CSF involvement and showing greater than 5% 
blasts, and 4) Patients with extramedullary relapse 
and showing less than 25% blasts.23 Groups 1 and 2 
received nelarabine 650 mg/m2 and groups 3 and 4 
received nelarabine 400 mg/m2 adjusted for neuro-
toxic adverse events in the individual groups. Group 1 
consisted of 33 subjects, of which 16 achieved a CR 
and two achieved a PR. Group 2 had 30 subjects with 
seven CRs and one PR. Of the 21 subjects in group 3, 
five achieved a CR and three achieved a PR. In the 
final group, only PRs were seen with three of the 
22   subjects showing this response.23
Demonstrated responses to nelarabine were seen in 
this trial in patients with refractory T-cell malignan-
cies, especially those with T-ALL in their first relapse. 
Further,  this  study  showed  that  of  those  patients 
with positive CSF involvement, eight of 22 patients 
achieved negative CSF cytology seven days subse-
quent to nelarabine treatment.23 Nelarabine resulted 
in a response (either CR or PR) in 37 of 106 patients 
and was the impetus for future trials in both the pedi-
atric and adult populations.23
The CALGB 59901 trial further evaluated nelar-
abine  in  cutaneous  and  peripheral  T-LBL.  This 
trial enrolled 19 patients with an age range of 33 to 
69 years. Eleven patients were diagnosed with cuta-
neous T-LBL and eight had peripheral T-LBL and all 
but five of the cutaneous T-LBL patients had prior 
local or systemic therapy.24 Study subjects received 
nelarabine 1.5 g/m2 on days one, three, and five and 
repeated every 21 days, which is similar to previous 
protocols. Results from this study showed only two 
subjects achieving a PR with no CR in any subject. 
This trial showed limited efficacy in the adult popula-
tion with T-LBL, which is in stark contrast to trials in 
pediatric patients, albeit in a small population with 
varying histologic subtypes of the disease.24
Gandhi, et al evaluated nelarabine in 35 patients 
with  indolent  leukemias  in  three  different  dosing 
protocols.25 Schedule A in this trial was daily weight-
based  dosing  of  nelarabine  for  five  consecutive 
days; schedule B consisted of alternate day dosing 
on days one, three, and five based on body surface 
area (BSA); schedule C consisted of a slightly lower 
BSA-based dose than schedule B given on alternate 
days for five days but included fludarabine infusions 
prior to the second and third doses of nelarabine per 
cycle. The subjects in this trial were heavily treated 
with  multiple  chemotherapeutic  regimens.  Overall 
and complete responses were 20% and 0%, 15% and 
5%, and 63% and 13% for schedules A, B, and C, 
respectively.25 This study exhibited a statistically sig-
nificant benefit with nelarabine with fludarabine as 
compared to nelarabine monotherapy. Responders in 
this study showed a median time to treatment fail-
ure of 17 months, and that response was not differ-
ent between the three treatment schedules. This study 
further demonstrated that nelarabine can show activ-
ity in mature T- and B-cell leukemias, especially in 
the presence of concomitant fludarabine.25
In a recently published study by Commander, et al, 
nelarabine was evaluated in combination as salvage 
therapy  in  seven  pediatric  patients  with  advanced 
T-ALL and T-LBL.26 Nelarabine was given at a dose 
of 650 mg/m2 per day for five days either before or 
after a dose of both etoposide and cyclophosphamide. 
Intrathecal prophylaxis was provided to all patients 
due  to  the  high  risk  of  CNS  relapse  in  patients Nelarabine in refractory T-cell malignancies
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with T-ALL.26 All five of the T-ALL patients achieved 
a CR and four of five went on to receive a hematopoi-
etic  stem  cell  transplant.  The  two  T-LBL  patients 
both had a PR with therapy and this is consistent with 
previous studies illustrating the difficulty in inducing 
a second remission in T-LBL patients.26 This study 
shows the need for further evaluation of nelarabine 
in combination therapy for these advanced hemato-
logic malignancies. Studies describing patients with a 
T-cell malignancy that have been treated with nelara-
bine have been summarized in Table 2.
Safety and Toxicity Profile
Central and peripheral neurotoxicity has been the most 
identifiable toxicity associated with nelarabine adminis-
tration. At the recommended adult dose of 1.5 g/m2, the 
incidence of motor and/or sensory peripheral neuropa-
thy was 21%.27 Multiple studies show varying degrees 
of peripheral neuropathy. Kurtzberg, et al showed that 
where  overall  incidence  of  reversible  neurotoxicity 
occurred more readily in adult patients than pediatric 
patients, incidence of grade 3 and 4 neurotoxicity was 
more common in the pediatric population.14 The most 
frequently reported central neurotoxicities are somno-
lence, malaise, and fatigue with onset of symptoma-
tology occurring most often within six to eight days 
following administration of nelarabine. Other neurotox-
icities include paresthesias, ataxia, tremor, neuropathy, 
amnesia, balance abnormalities, and sensory loss.27 The 
neurotoxicity associated with nelarabine is dose related 
with higher incidence with corresponding larger doses 
of the medication resulting in the dose-limiting toxicity 
often associated with regimens containing nelarabine.14
In the CALGB 19801 trial, authors reported grade 
3 fatigue and weakness in 18% and 11% of subjects, 
respectively.20,21 Lower grade peripheral sensory neu-
ropathy was also seen in this trial. The most common 
grade 3 and 4 adverse events in this trial were blood 
dyscrasias. Neutropenia, thrombocytopenia, and ane-
mia were all reported in the CALGB 19801 trial, but 
are  difficult  to  assess  because  many  patients  with 
T-ALL and T-LBL will have concomitant bone mar-
row involvement which could confound the causative 
agent responsible for these effects.20,21
Commander, et al described neurotoxicity in six 
of  seven  subjects  that  all  resolved  subsequent  to 
completion  of  nelarabine  therapy.  Due  to  the  pos-
tulated additive neurotoxicity in the study, as long 
as  administration  of  nelarabine  administration  and 
intrathecal chemotherapy were separated, there was 
no increased incidence of neurotoxicity.26 Czuczman, 
et al described grade 3 and 4 adverse events in 50% 
and 28% of patients, respectively. The most common 
of these were neurologic toxicities, although single 
episodes  of  grade  3  and  4  hematologic  toxicities 
occurred and were self-limiting.24 A recent case report 
describes  complete  paraplegia  in  a  T-ALL  patient 
treated with nelarabine. Ischemic, hemorrhagic, and 
leukemic infiltration were all ruled out as potential eti-
ologies and given the rapid loss of autonomic sensory 
and motor functions, the most plausible etiology was 
cumulative drug toxicity attributed to nelarabine.28
Of  importance  to  consider  within  the  scope  of 
nelarabine use is the concomitant risks of neurotox-
icity seen in patients with these malignancies. Many 
patients have previously been treated with neurotoxic 
Table 2. Summary of clinical trials with nelarabine administration in T-cell malignancies.
Trial Kurzberg  
et al 200514
DeAngelo 
et al 200721
Goy 
et al 200322
Berg et al 
200523
czuczman 
et al 200724
Gandhi 
et al 200825
commander 
et al 201026
evaluable  
patientsa
39 39 17 106 19 11 7
Diagnosis T-ALL, 
T-LBL
T-ALL,  
T-LBL
T-LBL T-ALL, 
T-LBL
Cutaneous 
and peripheral 
T-LBL
T-PLL T-ALL, 
T-LBL
Outcomes  
(%)b
CR 23.1% 30.8% 11.8% 26.4% 0% 5.7%c 71.4%
PR 30.8% 10.3% 35.3% 8.5% 10.5% 28.6%c 28.6%
notes:  awith T-cell malignancy receiving nelarabine;  bIncludes all diagnoses and trial doses;  cIncludes patients with B-cell lymphocytic leukemia as 
numbers were not reported per diagnosis. 
Abbreviations: T-ALL, T-cell acute lymphoblastic leukemia; T-LBL, T-cell lymphoblastic lymphoma; T-PLL, T-cell prolymphocytic leukemia; CR, complete 
response; PR, partial response.Roecker et al
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systemic  chemotherapy,  intrathecal  chemotherapy, 
radiation  therapy,  and  multiple  combinations  of 
these.14 It is difficult to individually assess a patient’s 
risk for neurotoxicity or if it is potentiated with nelar-
abine administration. It is certain that increased moni-
toring for multiple adverse effects must be done when 
nelarabine treatment is being considered.
conclusion
Nelarabine  is  FDA-approved  for  the  treatment  of 
T-cell leukemias and lymphomas in adult and pedi-
atric patients that have previously failed at least two 
chemotherapeutic regimens. It is a prodrug of ara-G 
that requires triphosphorylation prior to incorporation 
into T-cell DNA, which subsequently leads to pro-
grammed cellular death of these malignant cells.6–8 
Given the difficulty in treating these refractory malig-
nancies, data suggest that nelarabine as monotherapy 
can induce both complete and partial responses in 
patients with these cancers.14,20–23 The durability of 
these responses is still a topic that needs further elu-
cidation. Further, the risk of neurotoxicity as a dose-
limiting toxicity with nelarabine continues to hinder 
widespread  utility  outside  the  scope  of  advanced 
T-ALL and T-LBL.14,20,21,26 The use of nelarabine as 
part of a combination regimen may show increased 
benefit,25,26  but  more  research  is  needed  to  define 
nelarabine’s role in treating these very resistant and 
refractory cancers.
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